Dioxopromethazine HCl NEW

Liaoning Pharmaceutical Innovation Co., Ltd registered on September 16th, 2021, with a registered capital of 12 million RMB, is located in Chemical Industrial District, Panjin, Liaoning. It is a company engaged in the research, development, and production of active pharmaceutical ingredients and intermediates. The company is a subsidiary of Tianjin Pharmaceutical Innovation Co., Ltd. Tianjin P&I was established in July 2009 and is located in the Tianjin Binhai Development District. It is a high-tech enterprise specializing in the research, development, and production of active pharmaceutical ingredients and intermediates and providing pharmaceutical research and development outsourcing services. The company has a research and development center, a pilot workshop, and a GMP production base. It integrates research, pilot testing, and production, dedicated to providing high-quality pharmaceutical chemicals and contract manufacturing services to pharmaceutical companies worldwide. As a research-oriented and customer-centrist enterprise, it consistently strives to improve its technical innovation system. It prioritizes scientific and technological innovation, utilizes advanced and comprehensive production facilities, and has a robust quality assurance system to ensure the safe production of high-quality products. The company's progressive and innovative mindset, dedicated employees, and reasonable resource allocation are the solid foundation for the continuous development and growth of P&I. The company's main business covers various regions around the world. P&I has 47 patents, including six invention patents, all of which have been granted. Tianjin P&I is recognized as a national high-tech enterprise. After more than a decade of development, it has established a production system spanning small-scale research and development to pilot and industrial-scale mass production. It has also found improved process technology research for active pharmaceutical ingredients,